Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 2Gynecologic 1

Conditions

Breast Neoplasms 3Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Fulvestrant 127Trastuzumab 117Paclitaxel 113Letrozole 109pembrolizumab 81palbociclib 76pertuzumab 75Capecitabine 74Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 65exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 57Specimen Handling 51Surveys and Questionnaires 50Radiotherapy 50Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 42olaparib 40Standard of Care 36Biopsy 33sacituzumab govitecan 32130-nm albumin-bound paclitaxel 32Exercise 30Doxorubicin 30eribulin 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × 4-hydroxy-N-desmethyltamoxifen × 1 year × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT05607004 2025-10-30

EVANGELINE

Atossa Therapeutics, Inc.

Phase 2 Recruiting
87 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡